Axcella Health Inc. Announces Appointment of Catherine A. Sohn, Pharm. D. to its Board of Directors
“We are excited to welcome Dr. Sohn to our Board. She has over thirty years of global experience in the biopharmaceutical and consumer healthcare sectors and strong leadership and public company board experience, which will be instrumental to the continued advancement of our pipeline and execution of our strategy,” said
Dr. Sohn held a series of leadership positions in strategic product and business development and commercial operating roles at
“I am pleased to be joining the Board at an important time in Axcella’s evolution and to be working with Axcella’s experienced management team. I am excited by the Company’s current clinical studies and the potential of its platform.” said Dr. Sohn.
About Endogenous Metabolic Modulators
Endogenous metabolic modulators, or EMMs, are a broad family of molecules, including amino acids, which fundamentally impact and regulate human metabolism. Our AXA Candidates are anchored by EMMs that have a history of safe use as food. We believe that, unlike conventional targeted interventions currently used to address dysregulated metabolism, EMM compositions have the potential to directly and simultaneously support and modulate multiple metabolic pathways implicated both in complex diseases and overall health.
Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella’s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella’s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering. For more information, visit www.axcellahealth.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'Investors & News' section of our website at www.axcellahealth.com. We encourage investors and potential investors to consult our website regularly for important information about us.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the therapeutic potential of our AXA Candidates and our strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar words and expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words or expressions. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the clinical development and potential of our AXA Candidates, the potential impact on the Company of the board changes announced in this press release, the Axcella team’s ability to build a leading endogenous metabolic modulator company and to advance its pipeline and other risks identified in our